WEED Australia Ltd., a Public Company and Fully Reporting Under Australian Securities and Investment Commission (ASIC) Rules, Completes Five Full…

WEED Australia Ltd. is a majority (>99%) owned subsidiary of WEED, Inc (USA) and one of the first public Cannabis companies in Australia established in March 2017.

TUCSON, AZ / ACCESSWIRE / May 3, 2022 / WEED, Inc. (OTCQB:BUDZ) ("WEED" or the "Company") a global cannabis & hemp bioresearch company based in the USA, focused on the development and application of cannabis-derived compounds for the treatment of human and animal diseases, announced today that its subsidiary, WEED Australia Ltd. completed its financial statement requirements under ASIC RULES and intends to move forward with a formal public offering for WEED Australia later in 2022 or 2023 depending on market conditions. As a current reporting public company in Australia., (all financial statements have been prepared in accordance with The Corporations Act of 2001 and Australian Accounting Standards and interpretations of the Australian Accounting Standards Board.) WEED is currently looking for and talking to candidates to form strategic partnerships to join under its WEED umbrella.

Glenn E. Martin, WEED, Inc.'s Chief Executive Officer, will be traveling to WEED Australia's Gold Coast based headquarters in mid May 2022 to attend the exclusive "United in Compassion" conference May 20th to May 23rd. For more information on the conference please visit UnitedinCompassion.com.au

"WEED Australia looks to continue its R & D in clinical trials domestically as well as in Israel in conjunction with sister company, WEED Israel Cannabis Ltd. on product development and educational tools for doctors, health practitioners and the public. The Cannabis Institute of Australia, WEED Australia's non-profit arm will lead the charge" states Glenn E. Martin , "Our goal is to take care of the domestic Australian marketplace first, with both pharma and non pharma products to deepen knowledge and uses of Cannabis and its derivative forms from high THC to CBD & CBG compounds. Research is key to long term success. An informed customer is your best patient." Martin continues; "We believe the majority of discoveries in Cannabis and Hemp are yet to be found. These are exciting times that will change global health worldwide!

WEED, Inc.'s Subsidiaries past comments from 2021/2022

Story continues

WEED Israel (Cannabis) Ltd. "After over 2 years of putting human clinical trials and product development on hold due to COVID, WEED Israel is poised and anxious to build out our global brands in both pharmaceutical and non-pharmaceutical categories, starting with women's health and veterans' ailments (PTSD) to healthy green alternative medicines" stated Elliot Kwestel, Managing Director of WEED Israel (Cannabis) Ltd. based outside Jerusalem. Kwestel further commented, "WEED Israel looks to enrich and expand our clinical trials with both THC and Cannabinoid studies to promote healthy living for generations to come."

WEED Australia Ltd. and The Cannabis Institute of Australia (C.I.A.), our Australian non-profit arm, based in Queensland on the Gold Coast. Managing Director Patrick Brodnik stated, "With the new rules out governing cannabis & hemp in Australia and the announcement on 1st of February 2021 to allow over-the-counter CBD medicines in pharmacies, timing is perfect to begin our clinical trials in Israel and Australia to bring new curative products to market as we close out COVID mandates this year. Managing Director Brodnik continues, "This year 2022, we believe the future of decriminalizing cannabis and hemp globally will prove to be a giant leap forward for worldwide cannabis legalization."

WEED Hong Kong Ltd. Director Nicole Breen agrees, "The pandemic has affected all of us on a worldwide basis. Healing our planet with natural therapies, treatments and eventual "cures" utilizing natures' own Cannabaceae plant with its many properties, both with high tetrahydrocannabinol (THC) and cannabidiol (CBD) compounds, I believe will change the force of medicine forever in the years to come. We look forward to an exciting year end and a Prosperous 2022."

Caution Regarding Cannabis Operations in the United States

Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. While legal in certain states, cannabis remains a Schedule I drug under the U.S. Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable U.S. federal money laundering legislation. Investors should carefully read the risk factors and disclosures contained in our offering circular before making any decision to invest in our company.

Forward Looking Information

This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions, and include statements with respect to future revenue and profits. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Legal Notice

The information is provided for convenience only, is not investment advice and may not be relied upon in considering an investment in WEED, Inc. No representation or warranty, express or implied, is made as to the accuracy or completeness of any information contained herein, and any investment decision should be based solely on the information contained in the offering circular and related materials, and the investors independent research. No representation or warranty, express or implied, is made as to the future performance of any investment in WEED, Inc. or that investors will or are likely to achieve favorable results, will make any profit at all or will be able to avoid incurring a loss on their investment. In addition, prospective investors are encouraged to consult with their financial, tax, accounting or other advisors to determine whether an investment in WEED, Inc. is suitable for them.

Media Contact:Glenn E. Martin, CEO1-520-818-8582Glenn@WEEDincUSA.com

SOURCE: WEED, Inc.

View source version on accesswire.com: https://www.accesswire.com/699770/WEED-Australia-Ltd-a-Public-Company-and-Fully-Reporting-Under-Australian-Securities-and-Investment-Commission-ASIC-Rules-Completes-Five-Full-Years-of-Audited-Financials

The rest is here:

WEED Australia Ltd., a Public Company and Fully Reporting Under Australian Securities and Investment Commission (ASIC) Rules, Completes Five Full...